文献速递神经肿瘤

儿童高级别胶质瘤:表观遗传与激酶信号异常揭示新兴治疗机会

Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
PubMed 文献 · J Neurooncol · 2020-06-05

本文综述儿童高级别胶质瘤(pHGG)中表观遗传与激酶基因改变的治疗靶点。多种FDA批准或临床阶段激酶抑制剂可靶向BRAF/MET/NTRK/ALK及PI3K/EGFR/PDGFR/VEGF/AXL;表观遗传蛋白如HDAC、LSD1/JMJD3、EZH2、溴结构域、BMI-1亦可成药。单药试验结果不理想,受药代动力学差、适应性耐药和宽泛入组标准限制;多靶点联合治疗在选定生物标志物患者中可能更有前景。

要点

  • pHGG原发改变集中于表观遗传与激酶基因,为小分子靶向提供机会。
  • 可靶向激酶包括BRAF/MET/NTRK/ALK及PI3K/EGFR/PDGFR/VEGF/AXL。
  • 表观遗传靶点包括HDAC、LSD1/JMJD3、EZH2、溴结构域和BMI-1。

核心结论

  • pHGG的遗传和表型多样性已被大规模测序充分表征,但临床治疗范式尚未据此转变。
  • 靶向多个激酶或表观遗传靶点的联合治疗可能更有前景,尤其在选定的半球pHGG且有相关靶向治疗生物标志物的患者人群中尝试。

研究设计与样本

  • 通过针对性检索临床前文献和clinicaltrials.gov中pHGG的激酶与表观遗传通路,综述这些机制在临床前动物模型和当前临床试验中的靶向方式,并提出未来未探索的治疗可能。

主要发现

  • 相关pHGG激酶可被多种FDA批准或临床阶段激酶抑制剂靶向,包括改变的BRAF/MET/NTRK/ALK和野生型PI3K/EGFR/PDGFR/VEGF/AXL。
  • 涉及pHGG的表观遗传蛋白也可临床靶向,包括组蛋白擦除器、书写器和阅读器如HDACs、去甲基化酶LSD1/JMJD3、甲基转移酶EZH2、染色质阅读器溴结构域和染色质重塑亚基BMI-1。
  • 这些通路间可发生交叉对话,涉及EGFR和AMPK等激酶与HDACs或EZH2等表观遗传修饰因子相互作用。
  • 激酶抑制剂或表观遗传靶点单药试验结果不理想,受药代动力学差、适应性耐药和宽泛入组标准限制。

临床怎么用

  • 临床可考虑在选定的半球pHGG且有相关靶向治疗生物标志物的患者中尝试多激酶或多表观遗传靶点联合治疗。

局限性

  • 单药试验受药代动力学差、适应性耐药和宽泛入组标准限制。
  • 临床治疗范式尚未根据大规模测序信息转变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Supratentorial pediatric high-grade gliomas (pHGGs) are aggressive malignancies that lack effective treatment options. Deep genomic sequencing by multiple groups has revealed that the primary alterations unique to pHGGs occur in epigenetic and kinase genes. These mutations, fusions, and deletions present a therapeutic opportunity by use of small molecules targeting epigenetic modifiers and kinases that contribute to pHGG growth. METHODS: Using a targeted search of the pre-clinical literature and clinicaltrials.gov for kinase and epigenetic pathways in pHGG, we collectively describe how these mechanisms are being targeted in pre-clinical animal models and in current clinical trials, as well as propose unexplored therapeutic possibilities for future investigations. RESULTS: Relevant pHGG kinases are targetable by several FDA-approved or clinical-stage kinase inhibitors, including altered BRAF/MET/NTRK/ALK and wild-type PI3K/EGFR/PDGFR/VEGF/AXL. Epigenetic proteins implicated in pHGG are also clinically targetable and include histone erasers, writers and readers such as HDACs, demethylases LSD1/JMJD3, methyltransferase EZH2, chromatin reader bromodomains, and chromatin remodeler subunit BMI-1. Crosstalk between these pathways can occur involving kinases such as EGFR and AMPK interacting with epigenetic modifiers such as HDACs or EZH2. Single agent trial results of kinase inhibitors or epigenetic targets alone are underwhelming and hampered by poor pharmacokinetics, adaptive resistance, and broad inclusion criteria. CONCLUSIONS: The genetic and phenotypic diversity of pHGGs is now well characterized after large-scale sequencing studies on patient tissue. However, clinical treatment paradigms have not yet shifted in response to this information. Combination therapies targeting multiple kinases or epigenetic targets may hold more promise, especially if attempted in selected patient populations with hemispheric pHGG tumors and relevant targeted therapeutic biomarkers.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Sun Y, Bailey CP, Sadighi Z, et al. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities. J Neurooncol. 2020. PMID: 32504402. doi:10.1007/s11060-020-03546-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。